Characterization of antimitochondrial antibodies in healthy adults
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The detection of antimitochondrial antibodies (AMAs) is an important criterion for the diagnosis of primary biliary cirrhosis (PBC). During the last decade, the mitochondrial autoantigens have been cloned, sequenced, and identified as members of the 2-oxo-acid dehydrogenase pathway, including the E2 subunits of pyruvate dehydrogenase (PDC-E2), branched-chain 2-oxo-acid dehydrogenase (BCOADC-E2), and 2-oxo-glutarate dehydrogenase (OGDC-E2). We have developed a rapid and sensitive diagnostic test for use in PBC based on a triple hybrid recombinant molecule (r-MIT3) that contains the autoepitopes of PDC-E2, BCOADC-E2, and OGDC-E2. To help understand the frequency and antigen specificity of AMAs in an asymptomatic population and to identify patients with early disease, we investigated the prevalence of AMA, by enzyme-linked immunosorbent assay (ELISA), in a cohort of 1,530 people from northern Italy. Positive sera were further analyzed for immunoglobulin (Ig) isotypes, subclasses, and epitopes of AMA by a combination of ELISA and immunoblotting. In this cohort of 1,530 people, 9 (0.5%) reacted to r-MIT3 by ELISA. Of the 9 reactive sera, 2 recognized PDC-E2, 2 of 9 recognized BCOADC-E2, 1 of 9 recognized OGDC-E2, 2 of 9 recognized both PDC-E2 and BCOADC-E2, and 1 of 9 recognized PDC-E2 and OGDC-E2. AMA reactivity was primarily IgM and IgA. Epitope mapping revealed an AMA pattern of reactivity to PDC-E2 that differed from that found in patients with histologically proven PBC in most of the sera. However, 1 sera of a 72-year-old female with a normal alkaline phosphatase had an AMA profile identical to typical PBC. After a variable follow-up period (8-14 months), sera from 8 of 9 of these people were re-obtained for AMA and relative epitope mapping. Interestingly, the reactivity had a wider AMA pattern than before.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“AMA testing is not specific for PBC, and should always be targeted: the population frequency of AMA positivity is high (up to 1/1000) whereas PBC prevalence is lower (up to 0.4/1000) [42,43].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [42]
In the citing paper
“More recent large-scale blood donor and population studies have suggested that low titre AMA positivity in the context of normal LFTs is seen in ~0.5% of the population.85 86”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [85]
Citations
Cites
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Dominance and Crypticity of T Cell Antigenic Determinants
Sercarz, E. (1993) · Annual Review of Immunology · doi:10.1146/annurev.immunol.11.1.729 · Cited by 855
Kaplan, M. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611213352107 · Cited by 455
Natural history of early primary biliary cirrhosis
Metcalf, J. V., Mitchison, H. C., Palmer, J. M., Jones, D. E., Bassendine, M. F., & James, O. F. (1996) · The Lancet · doi:10.1016/s0140-6736(96)04410-8 · Cited by 421
Use of designer recombinant mitochondrial antigens in the diagnosis of primary biliary cirrhosis
Leung, P. S. C., Iwayama, T., Prindiville, T., Chuang, D. T., Ansari, A. A., Wynn, M. R., Dickson, R., Coppel, R., & Gershwin, E. M. (1992) · Hepatology · doi:10.1002/hep.1840150302 · Cited by 350
Self-citationMitchison, H. C., Bassendine, M. F., Hendrick, A., Bennett, M. K., Bird, G., Watson, A. J., & James, O. F. W. (1986) · Hepatology · doi:10.1002/hep.1840060609 · Cited by 230
Price, B. E., Rauch, J., Shia, M. A., Walsh, M. T., Lieberthal, W., Gilligan, H. M., O'Laughlin, T., Koh, J. S., & Levine, J. S. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.5.2201 · Cited by 206
Van de Water, J., Cooper, A., Surh, C. D., Coppel, R., Danner, D., Ansari, A., Dickson, R., & Gershwin, M. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198905253202104 · Cited by 201
Self-citationSurh, C. D., Coppel, R., & Gershwin, M. E. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.9.3367 · Cited by 167
Self-citationPengo, V, Biasiolo, A., Brocco, T., Tonetto, S., & Ruffatti, A. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650355 · Cited by 159
Research works printed but not linked: 5
- Myszor, 1990, Q J Med, 75, 377
- Leung, 1995, Hepatology, 22, 505
- Tsuneyama, 1995, Hepatology, 21, 1031
- Shlomchik, 1986, J Exp Med, 161, 88
- Sercarz, 1993, Annu Rev Immunol, 11, 729, 10.1146/annurev.iy.11.040193.003501 · doi:10.1146/annurev.iy.11.040193.003501 · Paper page
Cited by
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
“5% of the general population in Italy are AMA positive.(38) In a study from Japan, 11 of 1714 people (0.”
BackgroundCarey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 362
Selmi, C., Bowlus, C. L., Gershwin, M. E., & Coppel, R. L. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61965-4 · Cited by 334
Self-citationThe causes of primary biliary cirrhosis: Convenient and inconvenient truths
Gershwin, E. M., & Mackay, I. R. (2008) · Hepatology · doi:10.1002/hep.22042 · Cited by 274
Self-citationPrimary biliary cirrhosis: A 2010 update
Poupon, R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.11.027 · Cited by 274
“As in some other studies [13,14], the incidence of AMA positivity without evidence of liver disease was two times higher than the incidence of AMA positivity with evidence of liver disease.”
ResultHirschfield, G. M., & Heathcote, E. J. (2010) · Evidence‐Based Gastroenterology and Hepatology · doi:10.1002/9781444314403.ch32 · Cited by 261
Lleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31607-x · Cited by 253
Recent advances in the development of farnesoid X receptor agonists.
Ali, A. H., Carey, E. J., & Lindor, K. D. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2014.12.06 · Cited by 221
“AMA is a highly disease-specific autoantibody (114), rarely found in individuals without PBC (115).”
BackgroundLleo, A., Bowlus, C. L., Yang, G.-X., Invernizzi, P., Podda, M., Van de Water, J., Ansari, A. A., Coppel, R. L., Worman, H. J., Gores, G. J., et al. (2010) · Hepatology · doi:10.1002/hep.23783 · Cited by 216
Self-citationKumagi, T., & Heathcote, E. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-1 · Cited by 174
“5% of people in general population are also positive for AMA [42].”
Current understanding of primary biliary cholangitis
Tanaka, A. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0028 · Cited by 158
“AMAs are occasionally detected in less than 1% of healthy individuals with normal liver test results.(72,73) Individuals who are AMA-positive are at higher risk of developing PBC and require close follow-up, although the risk does not appear to be high, as previously believed.”
BackgroundOertelt, S., Rieger, R., Selmi, C., Invernizzi, P., Ansari, A. A., Coppel, R. L., Podda, M., Leung, P. S. C., & Gershwin, E. M. (2007) · Hepatology · doi:10.1002/hep.21583 · Cited by 168
“Demography Male: female ratio 3:87 1:29 NS Median age (years)* 67 [35–82] 64 [38–74] NS Median age at diagnosis (years)* 51 [19–70] 51 [33–71] NS Duration of disease (years)* 15 [1–36] 14 [3–28] NS Biochemistry ALT (UI/l)† 53 5 71 9 NS Alkaline phosphatase (UI/l)† 461 29 475 40 NS Bilirubin (mg/dl)† 0.”
Self-citationThe diagnosis of primary biliary cirrhosis
Bowlus, C. L., & Gershwin, M. E. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.041 · Cited by 162
Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis
O'Brien, C., Joshi, S., Feld, J. J., Guindi, M., Dienes, H. P., & Heathcote, E. J. (2008) · Hepatology · doi:10.1002/hep.22380 · Cited by 146
Dahlqvist, G., Gaouar, F., Carrat, F., Meurisse, S., Chazouillères, O., Poupon, R., Johanet, C., & Corpechot, C. (2017) · Hepatology · doi:10.1002/hep.28859 · Cited by 137
“Age (years) 247 60 (20-91) 229 58 (15-90) 0.”
BackgroundInfluentialYou, H., Ma, X., Efe, C., Wang, G., Jeong, S.-H., Abe, K., Duan, W., Chen, S., Kong, Y., Zhang, D., et al. (2022) · Hepatology International · doi:10.1007/s12072-021-10276-6 · Cited by 133
Lazaridis, K. N., Juran, B. D., Boe, G. M., Slusser, J. P., de Andrade, M., Homburger, H. A., Ghosh, K., Dickson, R. E., Lindor, K. D., & Petersen, G. M. (2007) · Hepatology · doi:10.1002/hep.21749 · Cited by 128
The epidemiology of primary biliary cirrhosis
Prince, M. I., & James, O. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00102-8 · Cited by 145
Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis
Leung, P. S. C., Rossaro, L., Davis, P. A., Park, O., Tanaka, A., Kikuchi, K., Miyakawa, H., Norman, G. L., Lee, W., & Gershwin, E. M. (2007) · Hepatology · doi:10.1002/hep.21828 · Cited by 121
Self-citationTsuda, M., Torgerson, T. R., Selmi, C. F., Gambineri, E., Carneiro-Sampaio, M. M. S., Mannurita, S. C., Leung, P. S. C., Norman, G. L., & Gershwin, M. E. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2010.06.017 · Cited by 118
Self-citationCirrhosis, W. S. (. V. F. C. P. G. F. P. B. (2014) · Hepatology Research · doi:10.1111/hepr.12270 · Cited by 125
Epidemiology of autoimmune liver disease
FELD, J., & HEATHCOTE, E. (2003) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2003.03165.x · Cited by 107
The X and why of xenobiotics in primary biliary cirrhosis
Rieger, R., & Gershwin, M. E. (2007) · Journal of Autoimmunity · doi:10.1016/j.jaut.2007.02.003 · Cited by 110
Padgett, K. A., Selmi, C. F., Kenny, T. P., Leung, P. S. C., Balkwill, D. L., Ansari, A. A., Coppel, R. L., & Gershwin, M. E. (2005) · Journal of Autoimmunity · doi:10.1016/j.jaut.2005.01.012 · Cited by 102
Self-citationDisease-specific autoantibodies in primary biliary cirrhosis
Bogdanos, D. P., & Komorowski, L. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.12.019 · Cited by 107
Antimitochondrial Antibodies: from Bench to Bedside
Colapietro, F., Lleò, A., & Generali, E. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08904-y · Cited by 95
Moritoki, Y., Lian, Z.-X., Wulff, H., Yang, G.-X., Chuang, Y.-H., Lan, R. Y., Ueno, Y., Ansari, A. A., Coppel, R. L., Mackay, I. R., et al. (2007) · Hepatology · doi:10.1002/hep.21522 · Cited by 80
Self-citationBizzaro, N., Covini, G., Rosina, F., Muratori, P., Tonutti, E., Villalta, D., Pesente, F., Alessio, M. G., Tampoia, M., Antico, A., et al. (2012) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8234-y · Cited by 79
“general population to discriminate the assay specificity [59].”
BackgroundSelf-citationThe limitations and hidden gems of the epidemiology of primary biliary cirrhosis
Podda, M., Selmi, C. F., Lleò, A., Moroni, L., & Invernizzi, P. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.06.015 · Cited by 76
Sun, C., Xiao, X., Yan, L., Sheng, L., Wang, Q., Jiang, P., Lian, M., Li, Y., Wei, Y., Zhang, J., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.01.005 · Cited by 66
Self-citationPrevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture
Shibata, M., Onozuka, Y., Morizane, T., Koizumi, H., Kawaguchi, N., Miyakawa, H., Kako, M., & Mitamura, K. (2004) · Journal of Gastroenterology · doi:10.1007/s00535-003-1285-6 · Cited by 64
Kisand, K. E., Metsküla, K., Kisand, K. V., Kivik, T., Gershwin, M. E., & Uibo, R. (2001) · Journal of Gastroenterology · doi:10.1007/s005350170111 · Cited by 56
Self-citationMethotrexate for primary biliary cirrhosis
Giljaca, V., Poropat, G., Stimac, D., & Gluud, C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004385.pub3 · Cited by 54
Serial Analysis of Antimitochondrial Antibody in Patients with Primary Biliary Cirrhosis
Benson, G. D., Kikuchi, K., Miyakawa, H., Tanaka, A., Watnik, M., & Gershwin, M. E. (2004) · Journal of Immunology Research · doi:10.1080/10446670410001722113 · Cited by 57
“In fact, random surveys of large numbers of healthy subjects have disclosed the presence of AMAs for several years before clinical diagnosis (Mattalia et al., 1998; Gershwin et al., 2000).”
BackgroundObeticholic acid for the treatment of primary biliary cholangitis
Ali, A. H., & Lindor, K. D. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1218471 · Cited by 47
The unfinished business of primary biliary cirrhosis
Selmi, C., Zuin, M., & Gershwin, M. E. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.06.006 · Cited by 50
“Hence, there is the need for rigorous population-based studies in different geographical areas that do not imply selection bias, as in the case of blood donors [8], or solid case-finding methods.”
Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis
Juliusson, G., Imam, M., Björnsson, E. S., Talwalkar, J. A., & Lindor, K. D. (2016) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2015.1132337 · Cited by 47
“sufficient to accurately diagnose the disease.[1,2] The 5–10% of patients who are AMA negative but”
BackgroundA Practical Review of Primary Biliary Cholangitis for the Gastroenterologist.
Onofrio, F. Q., Hirschfield, G. M., & Gulamhusein, A. F. (2019) · Europe PMC (PubMed Central) · Cited by 59
Natural History of Primary Biliary Cirrhosis
Mayo, M. J. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.012 · Cited by 52
Renaudineau, Y., Grunebaum, E., Krause, I., Praprotnik, S., Revelen, R., Youinou, P., Blank, M., Gilburd, B., Sherer, Y., Luderschmidt, C., et al. (2001) · Autoimmunity · doi:10.3109/08916930109008045 · Cited by 45
Self-citationMayo, I., Arizti, P., Parés, A. R., Oliva, J., Doforno, R. Á., de Sagarra, M. R., Rodés, J., & Castaño, J. G. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80003-3 · Cited by 44
Gong, Y., & Gluud, C. N. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41522.x · Cited by 43
Primary biliary cirrhosis among atomic bomb survivors in Nagasaki, Japan
Ohba, K., Omagari, K., Kinoshita, H., Soda, H., Masuda, J.-I., Hazama, H., Tagawa, M., Hata, T., Nakamura, H., Murata, I., et al. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00370-x · Cited by 37
Czul, F., Peyton, A., & Levy, C. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.12.003 · Cited by 40
Toward solving the etiological mystery of primary biliary cholangitis
Tanaka, A., Leung, P. S. C., Young, H. A., & Gershwin, M. E. (2017) · Hepatology Communications · doi:10.1002/hep4.1044 · Cited by 37
Self-citationRisk Factors and Prediction of Long-term Outcome in Primary Biliary Cirrhosis
Ishibashi, H., Komori, A., Shimoda, S., Ambrosini, Y. M., Gershwin, M. E., & Nakamura, M. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.4462 · Cited by 42
Primary biliary cirrhosis: new perspectives in diagnosis and treatment
Prince, M. I., & Jones, D. E. J. (2000) · Postgraduate Medical Journal · doi:10.1136/pmj.76.894.199 · Cited by 37
D-penicillamine for primary biliary cirrhosis
Gong, Y., Klingenberg, S. L., & Gluud, C. N. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004789.pub2 · Cited by 38
Colchicine for primary biliary cirrhosis
Gong, Y., & Gluud, C. N. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004481.pub2 · Cited by 38
Azathioprine for primary biliary cirrhosis
Gong, Y., Christensen, E., & Gluud, C. N. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006000.pub2 · Cited by 37
Primary biliary cirrhosis and autoimmune hepatitis: apotopes and epitopes
Lleò, A., Shimoda, S., Ishibashi, H., & Gershwin, M. E. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0303-8 · Cited by 32
Role of autoantibodies in the clinical management of primary biliary cholangitis
Rigopoulou, E. I., & Bogdanos, D. P. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i12.1795 · Cited by 30
Is There A Serological Difference Between Men and Women With Primary Biliary Cirrhosis?
Nalbandian, G., de Water, J. V., Gish, R. G., Manns, M. P., Coppel, R. L., Rudich, S. M., Prindiville, T. P., & Gershwin, E. M. (1999) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01380.x · Cited by 28
“BCOADC-E2, and OGDC-E2, as described elsewhere (30).”
Self-citationChanges in the Epidemiology of Primary Biliary Cholangitis
Lleò, A., & Colapietro, F. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.001 · Cited by 28
Apotopes and innate immune system: Novel players in the primary biliary cirrhosis scenario
Lleò, A., & Invernizzi, P. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.01.005 · Cited by 28
Zandanell, S., Straßer, M., Feldman, A., Tevini, J., Strebinger, G., Niederseer, D., Pohla‐Gubo, G., Huber-Schönauer, U., Ruhaltinger, S., Paulweber, B., et al. (2019) · Journal of Internal Medicine · doi:10.1111/joim.13005 · Cited by 27
Anti-mitochondrial autoantibodies
Fritzler, M. J., & Manns, M. P. (2002) · Clinical and Applied Immunology Reviews · doi:10.1016/s1529-1049(02)00058-2 · Cited by 30
Presentation and Diagnosis of Primary Biliary Cirrhosis in the 21st Century
Kumagi, T., & Onji, M. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.014 · Cited by 27
Natural history of primary biliary cirrhosis
Abe, M., & Onji, M. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00351.x · Cited by 26
Diagnosis and management of primary biliary cirrhosis
Ali, A. H., Carey, E. J., & Lindor, K. D. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.979792 · Cited by 24
“Further analysis revealed that the AMA pattern of reactivity differed from that seen in patients with histologically proven PBC [76].”
BackgroundAlvaro, D., Carpino, G., Craxì, A., Floreani, A., Moschetta, A., & Invernizzi, P. (2020) · Liver International · doi:10.1111/liv.14627 · Cited by 25
Patterns of disease progression and incidence of complications in primary biliary cholangitis (PBC)
Janmohamed, A., & Trivedi, P. J. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.002 · Cited by 21
Methotrexate for primary biliary cirrhosis
Gong, Y., & Gluud, C. N. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004385.pub2 · Cited by 27
Variant and Specific Forms of Autoimmune Cholestatic Liver Diseases
Dalekos, G. Ν., & Gatselis, N. (2019) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-019-00550-9 · Cited by 23
Cançado, G. G. L., Braga, M. H., Ferraz, M. L. G., Villela‐Nogueira, C. A., Terrabuio, D. R. B., Cançado, E. L. R., Nardelli, M. J., Faria, L. C., Gomes, N. M. D. F., Oliveira, E. M. G., et al. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07122-y · Cited by 22
Bittencourt, P. L., Farias, A. Q., Abrantes‐Lemos, C. P., Gonçalves, L. L., Gonçalves, P. L., MAGALHÃES, E. P., Carrilho, F. J., Laudanna, A. A., & Cançado, E. L. R. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2004.03396.x · Cited by 20
Muratori, P., Efe, C., Muratori, L., Ozaslan, E., Schiano, T., Yoshida, E. M., Heurgué-Berlot, A., Lalanne, C., Lenzi, M., & Wahlin, S. (2017) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000870 · Cited by 19
Cyclosporin A for primary biliary cirrhosis
Gong, Y., Christensen, E., & Gluud, C. N. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005526.pub2 · Cited by 22
Zografos, T. A., Gatselis, N., Zachou, K., Liaskos, C., Gabeta, S., Koukoulis, G. Κ., & Dalekos, G. N. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i34.4721 · Cited by 23
Carbone, M., Gerussi, A., Cardinale, V., Cazzagon, N., Cossiga, V., Lleò, A., Marrone, G., Marzioni, M., Moschetta, A., Muratori, L., et al. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.05.002 · Cited by 18
Emerging drugs for the treatment of Primary Biliary Cholangitis
Ali, A. H., Tabibian, J. H., Carey, E. J., & Lindor, K. D. (2016) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2016.1150999 · Cited by 19
Primary biliary cirrhosis and liver transplantation
Akamatsu (2012) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2012.v1.2.66 · Cited by 26
Berdichevski, T., Cohen‐Ezra, O., Pappo, O., & Ben‐Ari, Z. (2016) · Hepatology Research · doi:10.1111/hepr.12809 · Cited by 18
Autoimmune liver disease and multiple sclerosis: state of the art and future perspectives
Villani, R., Serviddio, G., Avolio, C., Cassano, T., & D’Amico, E. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01128-8 · Cited by 17
“It is estimated that 0.6% of the general population has AMA, whereas only 16% of patients with AMA develop PBC [115, 116].”
BackgroundInfluentialNew insights into autoimmune liver diseases
Kumagi, T., Alswat, K., Hirschfield, G. M., & Heathcote, J. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00366.x · Cited by 18
Primary biliary cirrhosis: From bench to bedside
Kouroumalis, E., & Notas, G. (2015) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v6.i3.32 · Cited by 21
Autoantibodies in Primary Biliary Cholangitis
Leung, K. K., & Hirschfield, G. M. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.004 · Cited by 17
Miyakawa, H. (1999) · Hepatology Research · doi:10.1016/s1386-6346(98)00088-6 · Cited by 16
A National Hospital‐Based Study of Hospitalized Patients With Primary Biliary Cholangitis
Manno, V., Gerussi, A., Carbone, M., Minelli, G., Taruscio, D., Conti, S., & Invernizzi, P. (2019) · Hepatology Communications · doi:10.1002/hep4.1407 · Cited by 15
“The proportion of males is largely variable, with a female to male (F:M) ratio of approximately 10:1,(1,9) which is possibly an overestimation because it goes down to 2:1 when restricted to antimitochondrial antibody positivity in the general population(3,10) and is close to 7:1 in the United Network for Organ Sharing…”
BackgroundBarrio, M. D., Díaz‐González, Á., & Alonso‐Peña, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167905 · Cited by 14
“It is known that not all patients with positive AMA present clinical features of PBC: frequency of AMA-M2 positivity in general population is set around 0.1–0.2% [3,13,14].”
InfluentialMawardi, M., Alalwan, A. M., Fallatah, H. I., Abaalkhail, F. A., Hasosah, M. Y., Shagrani, M. A., Alghamdi, M., & Alghamdi, A. (2021) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_112_21 · Cited by 14
“64%, respectively.[16,17] PBC is characterized by higher concordance in monozygotic twins than dizygotic twins.”
BackgroundFaisal, M. S., González, H. C., & Gordon, S. C. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.06.005 · Cited by 16
An Update on the Treatment and Follow-up of Patients with Primary Biliary Cholangitis
Burman, B. E., Jhaveri, M. A., & Kowdley, K. V. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.06.005 · Cited by 13
Washington, M. K., & Manns, M. P. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3398-8.00009-x · Cited by 12
Primary biliary cholangitis is more severe in previous hepatitis B virus infection patients
Zhang, Y., Shi, Y., Wu, R., Wang, X., Gao, X., & Niu, J. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001100 · Cited by 13
Li, C.-H., Xu, P.-S., Wang, C., & Zou, G. (2005) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.08.009 · Cited by 12
Lazaridis, K. N., & Lindor, K. D. (1999) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-999-0051-0 · Cited by 12
Cunha, L. M., Bittencourt, P. L., Abrantes‐Lemos, C. P., Moreira, A., Almeida, D., Paraná, R., & Andrade, Z. D. A. (2011) · Human Immunology · doi:10.1016/j.humimm.2011.10.001 · Cited by 13
Predicting and preventing autoimmunity: the case of anti-mitochondrial antibodies
Milkiewicz, M., Caballería, L., Smyk, D. S., & Milkiewicz, P. (2012) · Autoimmunity Highlights · doi:10.1007/s13317-012-0038-z · Cited by 11
Impact of Microbes on Autoimmune Diseases
Danzer, C., & Mattner, J. (2013) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-013-0216-3 · Cited by 11
“Despite being the diagnostic hallmark of PBC, antiPDC-E2 antibodies can occur in patients that do not have a florid liver disease (Mattalia et al. 1998; Metcalf et al. 1996).”
BackgroundHumoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis
Malyavantham, K. S., Weinstock‐Guttman, B., Suresh, L., Zivadinov, R., Shanahan, T., Badgett, D., & Ramanathan, M. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129503 · Cited by 10
Sakugawa, H., Nakasone, H., Nakayoshi, T., Yamashiro, T., Maeshiro, T., Kobashigawa, K., Kinjo, F., Saito, A., Zukeran, H., Nakanuma, Y., et al. (2003) · Hepatology Research · doi:10.1016/s1386-6346(03)00167-0 · Cited by 10
Azathioprine for primary biliary cirrhosis
Gong, Y., Christensen, E., & Gluud, C. N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006000 · Cited by 10
Evolving liver inflammation in biochemically normal individuals with anti-mitochondria antibodies
Baldo, D. C., Dellavance, A., Ferraz, M. L. G., & Andrade, L. E. C. (2019) · Autoimmunity Highlights · doi:10.1186/s13317-019-0120-x · Cited by 8
Lindor, K. D., & Levy, C. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0881-3.00041-3 · Cited by 9
Li, C.-H., Xu, P.-S., Wang, C., Zhang, Y., & Zou, G. (2006) · Rheumatology International · doi:10.1007/s00296-005-0034-y · Cited by 8
“In fact, naturally occurring AMAs with low titers were found in healthy adults [13, 14].”
Background
Metadata
- Authors
- Mattalia, A., Quaranta, S., Leung, P. S. C., Bauducci, M., Van de Water, J., Calvo, P. L., Danielle, F., Rizzetto, M., Ansari, A., Coppel, R. L., Rosina, F., & Gershwin, E. M.
- Affiliations
- University of California, Davis (US)
- Fondazione Ricerca Molinette (IT)
- Emory University (US)
- Monash University (AU)
- ORCID
- Venue
- Hepatology
- Published
- 1998-03
- Volume
- 27
- Issue
- 3
- Pages
- 656-661
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2148935965
- Cited by
- 146
- References
- 30
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 4 · 2023: 5 · 2022: 5 · 2021: 4 · 2020: 4 · 2019: 7 · 2018: 8 · 2017: 8 · 2016: 7 · 2015: 7 · 2014: 5 · 2013: 5 · 2012: 6
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6393 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 39588)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Dermatology › Autoimmune Bullous Skin Diseases
- Keywords
- antimitochondrial antibodies, primary biliary cirrhosis, mitochondrial autoantigens, PDC-E2, epitope mapping, early disease detection
- MeSH terms
- Adult, Aged, Autoantibodies, Female, Humans, Immunoglobulin G, Immunoglobulin Isotypes, Liver Cirrhosis, Biliary, Male, Middle Aged, Mitochondria, Recombinant Proteins, Epitope Mapping
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.